Events - Pharvaris N.V.

Upcoming Events

Jun 26, 2026 10:00 AM EDT

2026 Annual General Meeting of Shareholders

Add to Outlook

Add to Google Calendar

Supporting Materials

2025 Annual Report 4 MB

Convening Notice and Agenda 259.8 KB

Voting Proxy 198.5 KB

Past Events

Jun 28, 2024 9:00 AM EDT

2024 Annual General Meeting of Shareholders

Supporting Materials

Annual Report 2023 2.8 MB

Convening Notice and Agenda 58.2 KB

Voting Proxy 44.6 KB

Executed Minutes 474.2 KB

May 31 - Jun 3, 2024

European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.5 MB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 1.5 MB

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design 210.8 KB

Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks 134.6 KB

Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat 170.9 KB

Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases 358.6 KB

May 30 - Jun 2, 2024

2024 Eastern Allergy Conference (EAC)

Supporting Materials

Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema 212.3 KB

May 22 - May 24, 2024

20th Annual Congress of International Drug Discovery Science and Technology (IDDST)

Supporting Materials

Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema 1.3 MB

Apr 12 - Apr 13, 2024

CIIC Spring 2024 Conference

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 564.1 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 756.6 KB

Mar 15 - Mar 17, 2024

2024 HAE International (HAEi) Regional Conference Americas

Supporting Materials

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design 2.5 MB

Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 310 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 301.2 KB

Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.1 MB

Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey 622.8 KB

Mar 14 - Mar 16, 2024

3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA)

Supporting Materials

Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 2.5 MB

Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 356 KB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 281.3 KB

Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries 189.7 KB

Presentation - Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 4.8 MB

Poster - Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 2.5 MB

Mar 6, 2024 6:00 AM EST

Extraordinary Meeting of Shareholders

Supporting Materials

Convening Notice, Agenda, and Explanatory Notes 40.8 KB

Pharvaris Announces Extraordinary Meeting of Shareholders

Proposed Articles (English) 107.2 KB

Proposed Articles (Dutch) 131.7 KB

Voting Proxy 24 KB

EGM Meeting Minutes 388.1 KB

Feb 23 - Feb 26, 2024

American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 250.9 KB

Riedl Audio Recording 4.5 MB

Understanding Patient Reasons Not to Treat All Hereditary Angioedema Attacks and Patient Satisfaction With On-Demand Treatment: Results From the HAE Wave II Disease Specific Programme™(DSP™) 2023 183.7 KB

Mendivil Audio Recording 4.5 MB

Feb 4 - Feb 8, 2024

Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 366.6 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 264.3 KB

Pharvaris to Present at the WSAAI Annual Meeting 2024

Pagination

First page
Previous page
…
Page 5
Page 6
Current page 7
Page 8
Page 9
…
Next page
Last page

Presentations

Latest Corporate Presentation